Straits Times Index
3,287.25 -5.44 (-0.17%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,191.89 +428.86 (+2.41%) FTSE 100
8,157.63 +36.39 (+0.45%) Bitcoin USD
57,723.96 +617.62 (+1.08%) CMC Crypto 200
1,263.30 -7.44 (-0.59%)
Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 0.7080 |
| Open | 0.7300 |
| Bid | 0.7139 x 200 |
| Ask | 0.7207 x 200 |
| Day's range | 0.7121 - 0.7507 |
| 52-week range | 0.6710 - 5.9500 |
| Volume | |
| Avg. volume | 1,384,336 |
| Market cap | 29.523M |
| Beta (5Y monthly) | 2.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2400 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.75 |
Business WireSpruce Biosciences to Participate in May Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 01, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May.
Business WireSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 30, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatric
Business WireSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
